Chrystèle Locher

1.8k total citations
19 papers, 443 citations indexed

About

Chrystèle Locher is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Chrystèle Locher has authored 19 papers receiving a total of 443 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 8 papers in Oncology and 4 papers in Surgery. Recurrent topics in Chrystèle Locher's work include Lung Cancer Treatments and Mutations (10 papers), Lung Cancer Diagnosis and Treatment (7 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Chrystèle Locher is often cited by papers focused on Lung Cancer Treatments and Mutations (10 papers), Lung Cancer Diagnosis and Treatment (7 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Chrystèle Locher collaborates with scholars based in France, United States and French Polynesia. Chrystèle Locher's co-authors include Thomas Similowski, Éric Vérin, Jean‐Philippe Derenne, J. Le Treut, Alexandre Demoule, C. Chouaïd, A. Vergnenègre, C. Dujon, J.B. Auliac and H. Le Caer and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Applied Physiology and European Respiratory Journal.

In The Last Decade

Chrystèle Locher

17 papers receiving 436 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Chrystèle Locher France	10	321	184	104	65	47	19	443
Janet E. Olson United States	9	179 0.6×	228 1.2×	27 0.3×	112 1.7×	159 3.4×	14	472
Irini Youssef United States	11	79 0.2×	53 0.3×	64 0.6×	55 0.8×	85 1.8×	35	315
Linda Ofiara Canada	10	267 0.8×	114 0.6×	35 0.3×	141 2.2×	193 4.1×	23	441
Özlem Sönmez Türkiye	9	98 0.3×	105 0.6×	37 0.4×	12 0.2×	27 0.6×	42	288
Ethan I. Huang Taiwan	12	57 0.2×	170 0.9×	38 0.4×	27 0.4×	91 1.9×	45	373
Kristen Wroblewski United States	10	157 0.5×	42 0.2×	21 0.2×	120 1.8×	176 3.7×	18	450
Xiahui Ge China	11	166 0.5×	19 0.1×	50 0.5×	56 0.9×	129 2.7×	18	410
Mikael Victorzon Finland	9	102 0.3×	56 0.3×	22 0.2×	44 0.7×	93 2.0×	15	316
Yuval Nachalon Israel	12	132 0.4×	48 0.3×	22 0.2×	29 0.4×	94 2.0×	37	355
Himender Makker United Kingdom	7	320 1.0×	51 0.3×	23 0.2×	95 1.5×	259 5.5×	9	527

Countries citing papers authored by Chrystèle Locher

Since Specialization

Citations

This map shows the geographic impact of Chrystèle Locher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chrystèle Locher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chrystèle Locher more than expected).

Fields of papers citing papers by Chrystèle Locher

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chrystèle Locher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chrystèle Locher. The network helps show where Chrystèle Locher may publish in the future.

Co-authorship network of co-authors of Chrystèle Locher

This figure shows the co-authorship network connecting the top 25 collaborators of Chrystèle Locher. A scholar is included among the top collaborators of Chrystèle Locher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chrystèle Locher. Chrystèle Locher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Léna, H., Laurent Greillier, Claire Cropet, et al.. (2024). Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08–2015 ENERGY): a randomised, open-label, phase 3 study. The Lancet Respiratory Medicine. 13(2). 141–152. 5 indexed citations

Vergnenègre, A., I. Monnet, Charles Ricordel, et al.. (2023). Safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination in stage IV non-small-cell lung cancer: An open-label phase II trial (VinMetAtezo). Lung Cancer. 178. 191–197. 5 indexed citations

Treut, J. Le, G. Le Garff, Olivier Bylicki, et al.. (2022). Impact of KRAS G12C mutation in patients with advanced non-squamous non-small cell lung cancer treated with first-line pembrolizumab monotherapy. Lung Cancer. 174. 45–49. 8 indexed citations

Léna, H., Isabelle Monnet, Olivier Bylicki, et al.. (2022). Randomized phase III study of nivolumab and ipilimumab versus carboplatin-based doublet in first-line treatment of PS 2 or elderly (≥ 70 years) patients with advanced non–small cell lung cancer (Energy-GFPC 06-2015 study).. Journal of Clinical Oncology. 40(16_suppl). 9011–9011. 19 indexed citations

Debieuvre, D., Chrystèle Locher, Bernard Asselain, et al.. (2019). Evidence of slight improvement in five-year survival in non-small-cell lung cancer over the last 10 years: Results of the French KBP-CPHG real-world studies. Bulletin du Cancer. 106(4). 283–292. 15 indexed citations

Denis, Marc G., G. Le Garff, C. Dayen, et al.. (2019). Circulating free tumor-derived DNA to detect EGFR mutations in patients with advanced NSCLC: French subset analysis of the ASSESS study. Journal of Thoracic Disease. 11(4). 1370–1378. 13 indexed citations

Locher, Chrystèle, N. Pourel, H. Le Caer, et al.. (2018). Impact of a comprehensive geriatric assessment to manage elderly patients with locally advanced non-small–cell lung cancers: An open phase II study using concurrent cisplatin–oral vinorelbine and radiotherapy (GFPC 08-06). Lung Cancer. 121. 25–29. 9 indexed citations

Westeel, Virginie, Guillaume Eberst, Amélie Anota, et al.. (2018). Impact on health-related quality of life of the addition of bevacizumab to cisplatin-pemetrexed in malignant pleural mesothelioma in the MAPS phase III trial.. Journal of Clinical Oncology. 36(15_suppl). 8505–8505. 2 indexed citations

Caer, H. Le, N. Pourel, H. Bérard, et al.. (2018). Impact of a comprehensive geriatric assessment to manage elderly patients with locally advanced non-small-cell lung cancers: An open phase II study using concurrent cisplatin - oral vinorelbine and radiotherapy (GFPC 08-06).. Journal of Clinical Oncology. 36(15_suppl). e20513–e20513. 2 indexed citations

10.

Caer, H. Le, Isabelle Borget, R. Corre, et al.. (2017). Prognostic role of a comprehensive geriatric assessment on the management of elderly patients with advanced non-small cell lung cancer (NSCLC): a pooled analysis of two prospective phase II trials by the GFPC Group. Journal of Thoracic Disease. 9(10). 3747–3754. 13 indexed citations

11.

Auliac, J.B., I. Monnet, Catherine Dubos‐Arvis, et al.. (2017). Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocations: Clinical Characteristics and Management in a Real-Life Setting: a French Retrospective Analysis (GFPC 02–14 Study). Targeted Oncology. 12(6). 833–838. 8 indexed citations

12.

Zalcman, Gérard, Julien Mazières, J. Margery, et al.. (2015). Bevacizumab 15mg/kg plus cisplatin-pemetrexed (CP) triplet versus CP doublet in Malignant Pleural Mesothelioma (MPM): Results of the IFCT-GFPC-0701 MAPS randomized phase 3 trial.. Journal of Clinical Oncology. 33(15_suppl). 7500–7500. 20 indexed citations

13.

Chouaïd, C., C. Dujon, Pascal Dô, et al.. (2014). Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: A prospective multicenter study in a real-world setting (GFPC study 12-01). Lung Cancer. 86(2). 170–173. 132 indexed citations

14.

Debieuvre, D., Chrystèle Locher, Jacky Créquit, et al.. (2013). Major changes in men with non-small-cell lung cancer (NSCLC) in 10 years: The KBP-2000-CPHG and KBP-2010-CPHG cohorts. European Respiratory Journal. 42(Suppl 57). 1819–1819.

15.

Locher, Chrystèle, D. Debieuvre, D. Coëtmeur, et al.. (2013). Major changes in lung cancer over the last ten years in France: The KBP-CPHG studies. Lung Cancer. 81(1). 32–38. 74 indexed citations

16.

Locher, Chrystèle, Dominique Herman, D. Debieuvre, et al.. (2012). Study KBP-2010-CPHG: Characteristics and management of 7,051 new cases of lung cancer managed in French general hospitals in 2010.. Journal of Clinical Oncology. 30(15_suppl). 1574–1574.

17.

Locher, Chrystèle, Mathieu Raux, Marie‐Noëlle Fiamma, et al.. (2006). Inspiratory resistances facilitate the diaphragm response to transcranial stimulation in humans. BMC Physiology. 6(1). 7–7. 25 indexed citations

18.

Demoule, Alexandre, Éric Vérin, Chrystèle Locher, Jean‐Philippe Derenne, & Thomas Similowski. (2003). Validation of surface recordings of the diaphragm response to transcranial magnetic stimulation in humans. Journal of Applied Physiology. 94(2). 453–461. 71 indexed citations

19.

Vérin, Éric, Frédéric Sériès, Chrystèle Locher, et al.. (2002). Effects of neck flexion and mouth opening on inspiratory flow dynamics in awake humans. Journal of Applied Physiology. 92(1). 84–92. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact